巨细胞动脉炎

Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122-1128.

• 全文
• 摘要

Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594-1597.

• 全文
• 摘要

1.  Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287:92-101.

• 摘要

2.  Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234-245.

• 摘要

3.  Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol. 2006;18:10-17.

• 摘要

4.  Kermani TA, Matteson EL, Hunder GG, et al. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol. 2009;36:2277-2283.

• 摘要

5.  Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.

• 摘要

6.  Salvarani C, Gabriel SE, O'Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123:192-194.

• 摘要

7.  Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010;69:780-781.

• 摘要

8.  Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, et al. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis. 2001;60:367-371.

• 全文
• 摘要

9.  Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum. 1991;34:351-356.

• 摘要

10.  Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004;51:264-268.

• 全文
• 摘要

11.  Weyand CM, Hicok KC, Hunder GG, et al. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest. 1992;90:2355-2361.

• 全文
• 摘要

12.  Weyand CM, Ma-Krupa W, Pryshchep O, et al. Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci. 2005;1062:195-208.

• 摘要

13.  Weyand CM, Schonberger J, Oppitz U, et al. Distinct vascular lesions in giant cell arteritis share identical T-cell clonotypes. J Exp Med. 1994;179:951-960.

• 全文
• 摘要

14.  Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004;3:46-53.

• 摘要

15.  Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484-491.

• 摘要

16.  Nordborg E, Bengtsson BA. Epidemiology of biopsy-proven giant cell arteritis (GCA). J Intern Med[ 1990;227:233-236.

• 摘要

17.  Baldursson O, Steinsson K, Bjornsson J, et al. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum. 1994;37:1007-1012.

• 摘要

18.  Larsson K, Mellstrom D, Nordborg E, et al. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis. Ann Rheum Dis. 2006;65:529-532.

• 摘要

19.  Nordborg E, Nordborg C. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Rheumatology (Oxford). 2003;42:413-421.

• 全文
• 摘要

20.  Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Arterite a Cellules Geantes. Arthritis Rheum. 1998;41:1960-1965.

• 摘要

21.  Petursdottir V, Johansson H, Nordborg E, et al. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford). 1999;38:1208-1212.

• 全文
• 摘要

22.  Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120:987-992.

• 摘要

23.  Ray-Chaudhuri N, Kine DA, Tijani SO, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002;86:530-532.

• 摘要

24.  Ball EL, Walsh SR, Tang TY, et al. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surgery. 2010;97:1765-1771.

• 摘要

25.  Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142:359-369.

• 摘要

26.  Kermani TA, Warrington KJ. Recent advances in diagnostic strategies for giant cell arteritis. Curr Neurol Neurosci Rep. 2012;12:138-144.

• 摘要

27.  Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:1764-1772.

• 摘要

28.  Epperly TD, Moore KE, Harrover JD. Polymyalgia rheumatica and temporal arthritis. Am Fam Physician. 2000;62:789-796, 801.

• 摘要

29.  Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum. 2004;51:128-139.

• 全文
• 摘要

30.  Gertz MA, Kyle RA, Griffing WL, et al. Jaw claudication in primary systemic amyloidosis. Medicine (Baltimore). 1986;65:173-179.

• 摘要

31.  Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122-1128.

• 全文
• 摘要

32.  Fraser JA, Weyand CM, Newman NJ, et al. The treatment of giant cell arteritis. Rev Neurol Dis. 2008;5:140-152.

• 摘要

33.  Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594-1597.

• 全文
• 摘要

34.  Younge BR, Cook BE Jr, Bartley GB, et al. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin Proc. 2004;79:483-491.

• 摘要

35.  Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42:309-315.

• 全文
• 摘要

36.  Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85:1061-1064.

• 摘要

37.  Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309-1318.

• 摘要

38.  Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106-114.

• 摘要

39.  Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789-2797.

• 摘要

40.  Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310-3318.

• 摘要

41.  Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332-1337.

• 全文
• 摘要

42.  Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306-3309.

• 摘要

43.  Edwards MJ, Plant GT. Should we prescribe aspirin for patients with giant cell arteritis? A review of the evidence. Neuro-ophthalmology. 2009:33;1-4.

44.  Hoffman GS, Cid MC, Weyand CM, et al; Infliximab-GCA Study Group. Phase II study of the safety and efficacy of infliximab in giant cell arteritis (GCA): 22 week interim analysis. Rheumatology. 2005;44(suppl 3):iii18.

45.  Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73:2074-2081.

• 摘要

46.  Loock J, Henes J, Kötter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 2012;30(suppl 70):70-76.

• 摘要

47.  Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51:151-156.

• 摘要

48.  Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1921-1927.

• 摘要

49.  Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317-328.

• 摘要

50.  Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122:502-507.

• 摘要

51.  Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48:3532-3537.

• 全文
• 摘要

52.  Tomasson G, Peloquin C, Mohammad A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160:73-80.

• 全文
• 摘要

53.  Amiri N, De Vera M, Choi HK, et al. Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study. Rheumatology (Oxford). 2016;55:33-40.

• 摘要

54.  Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100:550-555.

• 摘要

55.  Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211-217.

• 摘要

56.  Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.

• 摘要

57.  Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res (Hoboken). 2011;63:761-765.

• 摘要

58.  Mackie SL, Hensor EM, Morgan AW, et al. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis. 2014;73:143-148.

• 摘要